Opaleye Management as of Sept. 30, 2019
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the September 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Codexis (CDXS) | 6.7 | $19M | 1.4M | 13.71 | |
| Stereotaxis (STXS) | 5.2 | $14M | 4.1M | 3.51 | |
| Epizyme | 5.1 | $14M | 1.4M | 10.32 | |
| Imprimis Pharmaceuticals | 4.8 | $13M | 2.4M | 5.62 | |
| Eidos Therapeutics | 4.0 | $11M | 306k | 35.97 | |
| Turning Point Therapeutics I | 3.9 | $11M | 288k | 37.60 | |
| Amarin Corporation | 3.5 | $9.8M | 645k | 15.16 | |
| Odonate Therapeutics Ord | 3.3 | $9.1M | 350k | 26.03 | |
| Ocular Therapeutix (OCUL) | 3.0 | $8.4M | 2.8M | 3.04 | |
| Axogen (AXGN) | 3.0 | $8.4M | 700k | 11.97 | |
| Uniqure Nv (QURE) | 2.9 | $8.1M | 205k | 39.36 | |
| Cara Therapeutics | 2.9 | $8.0M | 440k | 18.28 | |
| Audentes Therapeutics | 2.9 | $8.0M | 285k | 28.09 | |
| Deciphera Pharmaceuticals | 2.8 | $7.8M | 230k | 33.94 | |
| Blueprint Medicines (BPMC) | 2.8 | $7.7M | 105k | 73.47 | |
| Cytokinetics | 2.7 | $7.4M | 650k | 11.38 | |
| Xoma Corp Del (XOMA) | 2.7 | $7.4M | 375k | 19.71 | |
| Eton Pharmaceuticals (ETON) | 2.7 | $7.4M | 1.2M | 6.32 | |
| ACADIA Pharmaceuticals (ACAD) | 2.6 | $7.2M | 200k | 35.99 | |
| Cerecor | 2.6 | $7.2M | 2.2M | 3.29 | |
| Biohaven Pharmaceutical Holding | 2.4 | $6.7M | 160k | 41.72 | |
| Ptc Therapeutics I (PTCT) | 2.3 | $6.4M | 190k | 33.82 | |
| Tricida | 2.2 | $6.0M | 195k | 30.87 | |
| Avenue Therapeutics | 2.0 | $5.7M | 953k | 5.96 | |
| Fibrogen | 2.0 | $5.5M | 150k | 36.98 | |
| Shockwave Med | 1.7 | $4.8M | 160k | 29.93 | |
| Zymeworks | 1.5 | $4.2M | 170k | 24.80 | |
| Quanterix Ord (QTRX) | 1.5 | $4.1M | 185k | 21.96 | |
| Magenta Therapeutics | 1.4 | $4.0M | 385k | 10.26 | |
| Tg Therapeutics (TGTX) | 1.2 | $3.4M | 613k | 5.61 | |
| Ra Pharmaceuticals | 1.2 | $3.4M | 142k | 23.65 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.1 | $3.1M | 207k | 15.04 | |
| Synthorx | 1.1 | $2.9M | 180k | 16.27 | |
| Neoleukin Therapeutics | 1.0 | $2.8M | 995k | 2.85 | |
| Forty Seven | 1.0 | $2.7M | 425k | 6.42 | |
| Nextcure (NXTC) | 0.9 | $2.6M | 85k | 30.85 | |
| Fortress Biotech | 0.8 | $2.3M | 1.7M | 1.41 | |
| Radius Health | 0.7 | $1.9M | 75k | 25.75 | |
| Aptose Biosciences | 0.5 | $1.5M | 720k | 2.08 | |
| Flexion Therapeutics | 0.5 | $1.4M | 105k | 13.70 | |
| Edap Tms (EDAP) | 0.5 | $1.3M | 300k | 4.49 | |
| Chemocentryx | 0.5 | $1.4M | 200k | 6.78 | |
| Intra Cellular Therapies (ITCI) | 0.5 | $1.3M | 170k | 7.47 | |
| Strongbridge Bioph shs usd | 0.4 | $1.2M | 490k | 2.39 | |
| Cymabay Therapeutics | 0.3 | $717k | 140k | 5.12 | |
| Vermillion | 0.2 | $658k | 1.3M | 0.52 | |
| Assembly Biosciences | 0.2 | $492k | 50k | 9.84 | |
| Biolinerx Ltd-spons | 0.0 | $44k | 17k | 2.64 | |
| Proteon Therapeutics | 0.0 | $14k | 54k | 0.26 |
